ObjectiveaaRecent neuroimaging studies have suggested that brain changes occur in subjects at ultra-high risk (UHR) for psychosis while experiencing prodromal symptoms, among which depression may increase the risk of developing a psychotic disorder. The goal of this study is to examine brain metabolite levels in the anterior cingulate cortex, the left dorsolateral prefrontal cortex and the left thalamus in subjects at UHR for psychosis and to compare brain metabolite levels between the UHR subjects with comorbid major depressive disorder and healthy controls.
Introduction
Recently, structural brain changes in subjects at ultra-high risk (UHR) for psychosis have been reported in several brain regions, including the hippocampus 1,2 and anterior cingulate cortex (ACC). 3 However, the inconsistency of previous findings suggests us that subtle structural changes might occur before the onset of psychosis, which are not enough to be detected through the structural magnetic resonance imaging (MRI). Therefore, in vivo proton magnetic resonance spectroscopy ( 1 H-MRS) would greatly enhance our understanding of potential early brain changes in UHR subjects by assessing several brain chemicals such as N-acetylaspartate (NAA), creatine (Cr), choline (Cho), myo-inositol (Ins), glutamine and glutamate.
Few MRS studies have examined subjects at UHR for psychosis. Wood et al. 4 reported a significant increase in NAA/Cr and Cho/Cr ratios in the dorsolateral prefrontal region of the UHR group. Decreased NAA/Cr and NAA/Cho ratios in the left frontal lobe and decreased NAA/Cr ratios in the ACC were also reported in UHR subjects. 5 Recently, Aydin et al. 6 reported decreased NAA levels and prolonged T2 relaxation time of tissue water in the genu of the corpus callosum in the UHR cases as well as in the first-episode patients of developing schizophrenia. In addition, there was a report that brain metabolite such as NAA was correlated with duration of prodromal symptoms in the first-episode patients of developing schizophrenia. 13 On the other hand, depression is particularly common prodromal symptom in schizophrenia 7 and may increase the risk of developing a psychotic disorder. 8, 9 In several MRS studies examining patients with major depressive disorder (MDD), brain metabolite abnormalities were reported in several brain regions. 10, 11 In addition, reduced activation of the dorsolateral prefrontal regions was observed in subjects at high genetic risk of schizophrenia with depressive symptoms. 12 These findings suggest us that it is important to consider the influence of depression on brain metabolites status when examining neurochemical abnormalities in subjects at UHR for psychosis.
In this study, we primarily examined absolute value of brain metabolites in the ACC, the dorsolateral prefrontal cortex (DLPFC), and the left thalamus in subjects at UHR for psychosis. In addition, we examined differences in brain metabolites among UHR subjects with comorbid MDD, UHR subjects without MDD, and healthy subjects and investigated the correlation of brain metabolite levels with duration of prodromal symptoms. We used the absolute concentrations of metabolites in this study since relative concentrations using total Cr as an internal standard might result in false interpretation of data if Cr changed under certain conditions.
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Methods
Subjects
The subjects enrolled in this study were part of a prospective, longitudinal project investigating individuals at high risk for psychosis at the Seoul Youth Clinic.
The UHR group consisted of 20 subjects. UHR was determined based on the Comprehensive Assessment of At-Risk Mental States (CAARMS) criteria. 15 Individuals were considered as being at UHR if they met the criteria for UHR for psychosis and at least one of following: attenuated psychotic symptoms (APS), brief, limited intermittent psychotic symptoms (BLIPS), or trait plus state risk factors (T & S RF). Eighteen subjects met the intake criteria for APS and three met the T & S RF criteria. In addition, one subject met both the APS and T & S RF criteria. Eleven subjects in the UHR group (55%) were diagnosed with comorbid MDD, eight with anxiety disorder, and one with bipolar disorder, as determined via the Structured Clinical Interview for DSM-IV Axis I section (SCID). 16 Nine subjects were receiving psychotropic drugs at baseline (low-dose atypical antipsychotics, n=8; antidepressant, n=1).
The healthy control group consisted of 20 subjects who were age-and intelligence quotient (IQ)-matched to the UHR group. All were healthy adults aged 16-30 years with no lifetime history of any psychiatric disorder or treatment, and no first-to third-degree relatives with psychiatric disorders. These subjects were recruited via an Internet advertisement or through the social networks of hospital staff.
Exclusion criteria of the present study included a known history of psychotic illness lasting longer than 1 week, substance abuse or dependence, neurological disease, or brain injury; evidence of medical illness that could manifest psychiatric symptoms; and intellectual disability (IQ<70). All subjects provided written informed consent, and parental consent was obtained for subjects younger than 18 years of age. This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Seoul National University Hospital, Seoul, Korea.
Clinical interviews and assessments
Procedures for clinical interview and assessment are described in our previous report. 17 At intake, all potential subjects participated in an intensive clinical interview with two experienced psychiatrists who used the SCID 16 to identify past and current psychiatric illnesses. The UHR subjects were assessed using the CAARMS to ensure that the intake criteria were met. In addition, psychotic features were evaluated using a modified 24-item version of the Brief Psychiatric Rating Scale (BPRS; rating items 1-7) 18 and the Positive and Negative Syndrome Scale (PANSS). 19 The Hamilton Rating Scale for Depression (HAM-D), 20 and the Hamilton Rating Scale for Anxiety (HAM-A) 21 were also used to assess depressive and anxiety symptoms, respectively. The Korean version of the Wechsler Adult Intelligence Scale (K-WAIS) was administered to all subjects to obtain an estimated IQ.
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Magnetic resonance spectroscopy
All MRI and MRS experiments were performed using a Siemens 1.5-T system (Avanto, Germany) with a standard head coil. Foam padding and a forehead-restraint strap were used to limit head movement during the scan. T1-weighted images in three orthogonal planes were used for positioning volumes of interest (VOIs). All subjects were advised of the importance of remaining motionless during the procedure. Spectra consisting of 16 water-unsuppressed and 128 water-suppressed averages were acquired using a pointed resolved spin echo spectroscopy pulse sequence (TR= 6,000 ms, TE=40 ms, scan time=13 min/spectrum), which was selected to increase the reliability of glutamate+glu-tamine (Glx) in 1.5-T. 23 The raw data from each acquisition consisted of 2,048 points at a bandwidth of 2,500 Hz. The automatic shimming procedure built into the Siemens system was performed for each scan. The total examination time was approximately 60 min ( Figure 1 ).
Three VOIs were obtained from the ACC, the left DLPFC, and the left thalamus ( Figure 1 ). A 2×2×2 cm 3 VOI in the ACC was aligned perpendicularly to the tip of the genu of the corpus callosum and centered at the interhemispheric fissure. The midpoint of the left dorsolateral prefrontal voxel (2×1.5×2 cm 3 ) was positioned 7.5 mm anterior to the genu of the corpus callosum, and the VOI in the left thalamus was 1.5×2×2 cm 3 . Each VOI was carefully located on an axial slice to maximize the gray matter content for homogenous VOI selection by review of sagittal and coronal images.
Postprocessing and data analysis
Spectroscopic data (range, 4.2-1.0 ppm) were analyzed using LCModel (Ver 6.1-0), which has previously been used to identify low-concentration or overlapping metabolites. 24 To ensure that high-quality spectra were obtained, we verified that the full-width half-maximum for NAA peak was less than 0.08 ppm; if not, we reacquired MRS data from the region. Absolute quantifications were obtained through repeated trials using a calibration phantom with 50 mM NAA in a 250-cm 3 spherical flask. The segmentation of the MRI data into gray matter, white matter, and CSF components was accomplished using in-house software employing a fuzzy C-means algorithm. 25 We also corrected metabolite concentrations (C 0 ) for partial volume effects due to CSF by determining the fractional content of the CSF in the VOI (F CSF ) and applying the following correction:
Statistical analysis
Demographic information was compared using chisquare analyses, t-tests, and one-way analyses of variance (ANOVAs). Metabolite parameters were compared between groups via analysis of covariance, with age as a 
Results
Demographic and clinical data
No significant differences were observed between the UHR and healthy control groups in terms of age, sex ratio, or IQ. Mean age was 21.80±3.11 years for the UHR group and 22.0±4.11 years for the healthy controls (t= 0.695, p=0.491). The sex ratio (male/female) was 11/9 for the UHR group and 8/12 for healthy controls (χ 2 =0.902, p=0.342), and IQ scores were 110.25±14.39 for the UHR subjects and 112.05±9.74 for the healthy controls (t= 0.463, p=0.646). Table 1 provides information on the demographic and clinical characteristics among UHR subjects with MDD, UHR subjects without MDD, and healthy controls. Compared to the UHR subjects without MDD, UHR subjects with MDD scored significantly higher on the PANSS total, BPRS, and HAM-D (Table 1 ).
Brain metabolite data
No significant differences were observed in the absolute values of any metabolite in the ACC, left DLPFC, or left thalamus between the UHR group and healthy controls. However when we reanalyzed brain metabolite values according to MDD comorbidity among UHR subjects, a significant group effect was identified for Ins concentration in the left thalamus among UHR subjects with MDD, UHR subjects without MDD, and healthy controls (F=3.825, p=0.031). Tukey's post hoc test revealed a significant increase in Ins concentrations among UHR subjects with MDD relative to healthy controls (p=0.021; Figure 2 ) in the left thalamus. There were no significant differences in any other metabolite level in any brain region among UHR subjects with MDD, UHR subjects without MDD, or healthy controls (Table 2) .
To control the effect of medications in the UHR group, we performed additional analysis in drug-naïve UHR subjects (n=11). This analysis revealed that Ins concentrations increased significantly in the left thalamus of drug-naïve UHR subjects compared to healthy controls (Ins: F=5.032, p=0.033). Upon further analysis, however, a significant comorbidity effect was observed for Ins concentrations in the left thalamus among drug-naïve UHR subjects with MDD, those without MDD, and healthy controls (Ins: F=3.656, p=0.039), although the sample size was small. Tukey's post hoc test revealed that drugnaïve UHR subjects with MDD (n=6) showed increased Ins levels in the left thalamus compared to healthy controls (Ins: 3.55±0.75 versus 2.58±0.71, p=0.019). Using Pearson's correlation analysis, we found a significant positive correlation between Cho concentrations in the left thalamus and the duration of prodromal symptoms in the UHR group (r=0.495, p=0.027). In addition, we observed a trend toward positive correlation between thalamic Ins levels and the duration of prodromal symptoms in the UHR group (r=0.412, p=0.071). However, when the analysis was limited to UHR subjects with MDD, no significant correlation was observed between brain metabolite levels and clinical data.
Discussion
In the present study, no differences in brain metabolite levels within the ACC, left DLPFC, or left thalamus were observed between UHR subjects and healthy controls. However, a significant increase in Ins levels was observed in the left thalamus in UHR subjects with comorbid MDD compared to healthy controls. To our knowledge, this is the first report demonstrating alterations in brain metabolite levels in UHR subjects with comorbid MDD using 1 H-MRS. The level of brain metabolites obtained by MRS provides us much valuable information with the function of the brain in vivo, which is one of major strengths that MRS studies have. Although there are more than 6 brain metabolites that can be assessed by MRS, we investigated 6 molecules including NAA, Cho, Cr, Ins, and Glx, which have been examined in previous MRS studies of subjects at UHR or high genetic risk of psychosis and patients with schizophrenia. 5, 13, [26] [27] [28] NAA levels may represent sensitive means of monitoring neuronal cellular function. 29, 30 Cho levels can be used as an indicator of membrane turnover. Cr levels represent cellular energy metabolism. Ins is found primarily in glial cells and can be used as a marker of glial cell function. 31 Increased Glx concentrations are reported to be related with excitotoxicitiy. 27 Contrary to previous MRS studies, 1 H-MRS did not reveal any significant alteration in brain metabolite levels in the UHR group. The results of two previous studies investigating brain metabolites in UHR subjects were inconsistent in this regard. For example, Jessen et al. 5 reported that NAA/Cr ratios decreased in the frontal lobe, whereas Wood et al. 4 reported increased NAA/Cr ratios in the frontal lobe. In addition, these studies did not account for between-group age differences, medications, or comorbidity. In this study, we addressed the potential confounding effects of medication by performing an additional analysis in drug-naïve UHR subjects (n=11), which revealed a significant increase in Ins concentrations in the left thalamus compared to healthy controls. However, these differences were influenced by the presence of comorbid MDD; only drug-naïve UHR subjects with MDD showed higher Ins than healthy controls. Depression is one of the most frequent prodromal symptoms and the occurrence of depressive symptoms appears to have prognostic implications for the type and severity of symptoms in first-episode psychosis. 7 Moreover, Yung et al. 8 reported that severe depression was a predictor of psychosis. Of particular interest, we observed a significant increase in Ins concentrations in the left thalamus in UHR subjects with MDD compared to healthy controls. The thalamus is an important component of the limbic system that plays a role in the processing of emotion, and thalamic dysfunction is involved in the pathophysiology of MDD. [32] [33] [34] [35] Structurally, Young et al. 33 reported that the number of neurons in the thalamus increased in patients with MDD compared to healthy controls. Functionally, thalamic metabolism 36 and restingstate thalamic functional connectivity 34 increased significantly in patients with MDD. To date, however, only few MRS studies have examined the role of the thalamus in MDD, 37, 38 instead, the majority of studies focused on the DLPFC, ACC or basal ganglia. In the present study, increased thalamic Ins concentrations suggest that the disruption of secondary messenger systems may occur in UHR subjects with MDD. Ins is an important constituent of the phosphatidylinositol (PI) secondary messenger system. Given that the human brain obtains most of its Ins supply from resynthesis through the PI cycle and that diverse receptors are coupled to the PI cycle, 39 alterations in the Ins level may influence specific neuronal ganglia. In addition, dysfunction in the coupling metabolism of the receptor-secondary messenger system complex may provide an important biological substrate to UHR subjects experiencing prodromal depressive symptoms. Ins may also be a useful glial marker 40 and stored in glial cells before its consumption in the PI cycle of neurons. 41 Therefore, alterations in the Ins level may represent astroglial dysfunction that can be one of the possible biological mechanism of prodromal depressive symptoms in UHR subjects, although this hypothesis still need to be more investigated to be verified.
There were significant differences in PANSS total and BPRS scores between UHR subjects with MDD and those without MDD. To exclude the possible effect of PANSS total score difference on increased Ins concentrations in the UHR group with MDD, after stratifying the UHR group according to mean PANSS total score, no significant difference in Ins levels in the left thalamus was observed between UHR subjects with high PANSS total scores (PANSS score ≥56, n=11), UHR subjects with low scores, and healthy controls (F=1.847, p=0.172). Therefore, comorbid MDD may account for the observed increase in Ins concentrations in UHR subjects.
A trend toward a positive correlation between thalamic Ins levels and the duration of prodromal symptoms, and a significant positive correlation between Cho concentrations in the thalamus and the duration of prodromal symptoms were observed in the UHR group. As Cho is a primary constituent of cell membrane phospholipids, increased Cho levels can be interpreted as increased membrane turnover. Théberge et al. 13 found a positive correlation between Cho levels in the left ACC and left thalamus and the duration of untreated psychosis, supporting the concept that Cho functions as a disease activity marker. Similarly, our results may indicate that disease-related processes, such as increased membrane turnover, may be occurring in UHR subjects, although we did not observe a significant difference in Cho concentrations between the UHR group and the healthy controls.
Our study has some important limitations. First, we were unable to include patients with schizophrenia. But although comparing brain metabolite values between UHR subjects and patients with schizophrenia was impossible, alterations in Ins levels according to comorbid MDD among UHR subjects would be convincing of elucidating the effect of depressive symptoms on brain of individuals at UHR for psychosis. Second, our sample size was small. Additional analysis to control the effect of comorbid MDD and medication might have possibilities to lower the statistical power. However, the other MRS studies about the UHR subjects and first episode schizophrenia also had a limitation with the number of subjects due to the rarity of the subject group. 4, 42 Therefore, a longitudinal follow-up investigation with a larger sample size is required in the future. In addition, comorbid anxiety disorder and bipolar disorder were not excluded in this study. Alteration of brain metabolites such as lactate, GABA, Ins is reported in subjects with anxiety disorder and bipolar disorder. 40, 43 In summary, our results demonstrate that increased thalamic Ins concentrations are associated with prodromal depressive symptoms in UHR subjects. More MRS studies in UHR subjects with longitudinal design will be needed to discover a biomarker of vulnerability to psychosis.
